ライフサイエンスコーパス: checkpoint

1 cell-mediated immune response (called immune checkpoints).

2 pacity and silencing of the spindle assembly checkpoint.

3 RB, implying that they have a functional G1 checkpoint.

4 chromosome bridges via the NoCut abscission checkpoint.

5 oint and before the mTOR-mediated cell cycle checkpoint.

6 cy of the immunoprotective PD-1/PD-L1 immune checkpoint.

7 PC localization to chromatin and the mitotic checkpoint.

8 cells recover from activation of the S-phase checkpoint.

9 cently recognized transcriptional regulatory checkpoint.

10 pendent kinases 2 and 4/6 at G1/S cell-cycle checkpoint.

11 ecessary for the inactivation of the mitotic checkpoint.

12 promotes override of the replication stress checkpoint.

13 e dependence on ATR/CHK1-mediated cell cycle checkpoints.

14 n of p53, an effector of the pre-Ag receptor checkpoints.

15 tion represent separable, "tunable" fidelity checkpoints.

16 he efficacy of therapeutics targeting cancer checkpoints.

17 requires two independent S-phase cell-cycle checkpoints.

18 M1 mRNA bypasses the normal quality-control checkpoints.

19 versible nature of three specific cell-cycle checkpoints.

20 components (MCMs) and mediator of DNA damage checkpoint 1 (MDC1) expression.

21 Here, we review another checkpoint acting to potentiate the activity of innate i

22 d in replication fork stabilization, S-phase checkpoint activation and establishment of sister chroma

23 e-strand breaks (DSBs) is essential for both checkpoint activation and homology-mediated repair; howe

24 Furthermore, checkpoint activation does not occur in response to DNA

25 Recovery from checkpoint activation is critical for cell survival foll

26 Therefore, Mps1 promotes checkpoint activation through sequentially phosphorylati

27 olic conversion of ANI-7 induces DNA damage, checkpoint activation, S-phase cell cycle arrest, and ce

28 ll-cycle arrest, consistent with replication checkpoint activation.

29 on, Dia2 physically interacts with Sgs1 upon checkpoint activation.

30 The spindle checkpoint acts as a mitotic surveillance system, monito

31 red for rapid inactivation of the DNA damage checkpoint after DSB repair.

32 B and surface IgM constitute a rate-limiting checkpoint against B cell dysregulation by MYD88(L265P)

33 This checkpoint is located after the Gln checkpoint and before the mTOR-mediated cell cycle check

34 Regulation of this checkpoint and sensitivity to topo II-targeted drugs is

35 PTEN inhibition releases deltaR from this checkpoint and stimulates delivery of exogenous and endo

36 itivity to inhibitors of the DNA replication checkpoint and suggesting it as a candidate biomarker fo

37 tential of combined disruption of inhibitory checkpoints and CAR T cell therapy remains incompletely

38 ATR is a key regulator of cell-cycle checkpoints and homologous recombination (HR).

39 These checkpoints are governed by protein-interaction networks

40 creased DNA polymerase alpha was followed by checkpoint arrest due to phosphorylation of checkpoint k

41 ctive Pkc1 can drive cells through a mitotic checkpoint arrest, which suggests that Pkc1-dependent ac

42 racteristic 'VSG synthesis block' cell-cycle checkpoint, as some cells reinitiated S phase.

43 Here we define a signaling-regulated checkpoint at the trans-Golgi network (TGN) that control

44 ose that SOCE controls a critical "metabolic checkpoint" at which T cells assess adequate nutrient su

45 form the rationale for the design of immune checkpoint-based immunotherapy in the future.

46 Strikingly, although combination checkpoint blockade (anti-CTLA-4 + anti-PD-1) was ineffe

47 of checkpoint blockade immunotherapy.Immune checkpoint blockade (ICB) therapies can unleash anti-tum

48 advanced cancer patients treated with immune checkpoint blockade (ICB).

49 e elicited by the combined actions of immune checkpoint blockade agents together with targeted agents

50 ate the complex nature of immune response to checkpoint blockade and the compelling need for greater

51 Immune checkpoint blockade appears to be a promising approach f

52 n in the immune repertoire immediately after checkpoint blockade can be both detrimental and benefici

53 While immune checkpoint blockade elicits efficacious responses in man

54 40 triggering with ISF35 in combination with checkpoint blockade for multifocal cancer, including the

55 ion and monitoring of responders to clinical checkpoint blockade has been the lack of imaging tools t

56 Immune checkpoint blockade has emerged as a promising cancer tr

57 Immune checkpoint blockade has revolutionized cancer treatment.

58 Combinatorial studies with immune checkpoint blockade have started and the results are awa

59 Checkpoint blockade immunotherapies enable the host immu

60 Cytokine and immune checkpoint blockade immunotherapy for metastases was com

61 oantigen-specific T cells and the effects of checkpoint blockade immunotherapy.Immune checkpoint bloc

62 f the landmark clinical trials investigating checkpoint blockade in lung cancer and mesothelioma is p

63 Response to immune checkpoint blockade in mesenchymal tumors is poorly char

64 spensable for the antitumor effect of immune checkpoint blockade in mice.

65 the context of ionizing radiation and immune checkpoint blockade in vivo.

66 activation of CD4(+) T lymphocytes by immune checkpoint blockade increased vessel normalization.

67 Immune-checkpoint blockade is able to achieve durable responses

68 The mechanisms by which immune checkpoint blockade modulates tumor evolution during the

69 this approach, alone and in combination with checkpoint blockade or other immunotherapies.

70 milar between tumor models and indicate that checkpoint blockade targets only specific subsets of tum

71 nding of the molecular mechanisms underlying checkpoint blockade therapies will facilitate the design

72 rs in combination with other existing immune checkpoint blockade therapies.

73 Immune checkpoint blockade therapy (ICBT), which blocks negativ

74 shed data from two clinical trials of immune checkpoint blockade therapy for metastatic melanoma, we

75 with CDK4/6 inhibitors and PD-1-PD-L1 immune checkpoint blockade to enhance therapeutic efficacy for

76 as appears inflamed and responsive to immune checkpoint blockade with programmed death 1 (PD-1) targe

77 ic reprogrammability (for example, to immune checkpoint blockade) is not well understood.

78 t cancers, referred to generically as immune checkpoint blockade, and conversely to treat autoimmunit

79 ing under adoptive T-cell transfer or immune checkpoint blockade, arguing for an adaptive resistance

80 ed overwhelming de novo resistance to immune checkpoint blockade, motivating a search for targeted th

81 icient cancers make them sensitive to immune checkpoint blockade, regardless of the cancers' tissue o

82 nt metastatic melanoma tumors taken prior to checkpoint blockade, which revealed biological signature

83 esponders were refractory to previous immune checkpoint blockade.

84 T cells is potentially important for immune checkpoint blockade.

85 anoma requires predictors of the response to checkpoint blockade.

86 trategy to drive systemic efficacy of immune checkpoint blockade.

87 suppress MDSC to enhance responses to immune checkpoint blockade.

88 es that combine genotoxic agents with immune checkpoint blockade.

89 may complement antitumor activity of immune checkpoint blockade.

90 ficantly increased the efficacy of anti-PD-1 checkpoint blockade.

91 e that synergize with or cause resistance to checkpoint blockade.

92 n (abscopal effect) in the context of immune checkpoint blockade.

93 Immune-checkpoint-blockade (ICB)-mediated rejuvenation of exhau

94 ined with additional immunotherapies such as checkpoint blockades, the nanovaccine demonstrates subst

95 Immune checkpoint blockers (ICB) have become pivotal therapies

96 ave been excluded from most trials of immune checkpoint blocking agents, such as anti-PD-1 and anti-P

97 We also found that immune checkpoint-blocking (ICB) antibodies against programmed

98 ATR inhibition to abrogate the G2 cell cycle checkpoint both contributed to the synergistic induction

99 n several components of the spindle assembly checkpoint but does require the kinetochore, as depletin

100 The blockade of immune checkpoints by anti-receptor and/or anti-ligand mAb is o

101 of chromosomal instability and phagocytosis checkpoints by apoptotic cancer stem cells.

102 nd murine cells impairs the spindle assembly checkpoint, centrosome and spindle function, and mainten

103 -Mad2-Cdc20 is incorporated into the mitotic checkpoint complex (MCC), which inhibits the anaphase-pr

104 ckpoint proteins, in the form of the mitotic checkpoint complex (MCC), with the APC/C. apc14Delta mut

105 Knl1, when phosphorylated by Mps1, recruits checkpoint complexes Bub1-Bub3 and BubR1-Bub3 to unattac

106 enase complex (PDC) is the primary metabolic checkpoint connecting glycolysis and mitochondrial oxida

107 IL-12 (G47Delta-mIL12), antibodies to immune checkpoints (CTLA-4, PD-1, PD-L1), or dual combinations

108 on was a targeted (BRAF or MEK) or an immune checkpoint (cytotoxic T-lymphocyte-associated antigen 4

109 ive in poly-ubiquitination of Cdc20, and are checkpoint defective.

110 volution of fast-growing clones with mitotic checkpoint defects.

111 ntain genomic stability including cell cycle checkpoints, DNA repair, protein ubiquitination, chromat

112 A (stop-signal) at the centre of a molecular checkpoint downstream of GPIb that controls transendothe

113 response, PSGL-1 has emerged as an important checkpoint during this process.

114 with the APC/C and are unable to silence the checkpoint efficiently.

115 The spindle assembly checkpoint ensures the faithful inheritance of chromosom

116 emergency program evaded genomic instability checkpoint, expressed genomic instability-associated gen

117 sis revealed major differences in the immune checkpoint expression patterns across tumor types and in

118 ng tools to accurately assess dynamic immune checkpoint expression.

119 er that involves downregulation of microglia checkpoints, followed by activation of a Trem2-dependent

120 genesis and increases reliance upon the G2-M checkpoint for adaptation to stress and DNA repair, maki

121 onstruction of these functional centers is a checkpoint for committing to spacer removal.

122 , and cytokine signals provides a peripheral checkpoint for DNA-containing antigens that, if circumve

123 Here we report that IL-1R8 serves as a checkpoint for NK cell maturation and effector function.

124 that the ARF-NRF2 interaction acts as a new checkpoint for oxidative stress responses.

125 cts in boi mutant cells, and abrogated NoCut checkpoint function.

126 proaches in immunotherapy that target immune checkpoints have shown great promise in a variety of can

127 though some clinical trials targeting immune checkpoints have shown success, the molecular mechanism

128 lti-target phosphorylation cascade makes the checkpoint highly responsive to Mps1 and to kinetochore-

129 ating cancer resistant to therapy, including checkpoint immunotherapies, and early tumor resection an

130 sary to increase the therapeutic efficacy of checkpoint immunotherapy.

131 that ATR controls a DNA damage-induced G2/M checkpoint in cortical progenitors, independent of ATM a

132 ta suggest that RIPK1 may mediate a critical checkpoint in the transition to the DAM state.

133 l epsilon) was shown to activate the S-phase checkpoint in yeast in response to replicative stress, b

134 adversely impacted upon the DSB-induced G2-M checkpoint, inducing a hypersensitive and prolonged arre

135 tation to stress and DNA repair, making G2-M checkpoint inhibition a target for novel therapeutic dev

136 Using a combination of immune-checkpoint inhibition and plasmonic gold nanostar (GNS)-

137 nd the potential benefit of continued immune checkpoint inhibition beyond progression.

138 Immune tolerance checkpoint inhibition has been transformative in promoti

139 In the past 5 years, success of immune checkpoint inhibition has led to a resurgence of enthusi

140 in addition to early cytokine therapy, newer checkpoint inhibition therapies have also demonstrated a

141 in immunologic tumor therapy, which include checkpoint inhibition, mAbs, and engineered T-cell antig

142 ed nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for safety and activity i

143 treatment response were assessed across four checkpoint inhibitor datasets.

144 c cancers for trials of certain targeted and checkpoint inhibitor drugs.

145 In this first evaluation of an immunologic checkpoint inhibitor in healthy HIV-1-infected persons,

146 on and highlight how it may act as an immune checkpoint inhibitor in T cells.

147 e we show that ILC2s dynamically express the checkpoint inhibitor molecule PD-L1 during type 2 pulmon

148 el count to be significantly associated with checkpoint inhibitor response across three separate mela

149 Finally, analysis of checkpoint inhibitor response data revealed frameshift i

150 The response rate to immune checkpoint inhibitor therapy for non-small-cell lung can

151 TNBCs that could derive benefit from immune checkpoint inhibitor therapy to tilt the balance in favo

152 , biopsy specimens from melanoma patients on checkpoint inhibitor therapy were analyzed.

153 etastatic tumors, including PDACs, to immune checkpoint inhibitor therapy.

154 Previous treatment with one immune-checkpoint inhibitor was permitted.

155 ntent during therapy and a responder given a checkpoint inhibitor-based regimen because of a mismatch

156 evaluate addition of an oncolytic virus to a checkpoint inhibitor.

157 success has been achieved with the class of checkpoint inhibitors (CPIs), antibodies that unleash th

158 Recently, immune checkpoint inhibitors (ICI), in single agent and combina

159 Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 ax

160 chimeric antigen receptor (CAR) T cells and checkpoint inhibitors (including antibodies that antagon

161 , which may work synergistically with immune checkpoint inhibitors and other strategies in the treatm

162 The development of CD47-SIRPalpha checkpoint inhibitors and the potential side effects tha

163 e in cancer patients, with other interesting checkpoint inhibitors being currently in development.

164 Immune checkpoint inhibitors have demonstrated atypical respons

165 icroenvironment, including the use of immune checkpoint inhibitors in selected DLBCL subsets, and the

166 epair are associated with response to immune checkpoint inhibitors in several other cancer types.

167 dicates that double blockade with two immune checkpoint inhibitors increases the number of tumor-infi

168 The success of immunotherapy with checkpoint inhibitors is not replicated in most cases of

169 mediating the anti-cancer effects of immune checkpoint inhibitors when combined with SMCs.

170 (+) T cell (TCD8) responses, and PD-1-based "checkpoint inhibitors" have shown promise in certain can

171 Immune checkpoint inhibitors, including those targeting CTLA-4/

172 ge response, angiogenesis inhibitors, immune checkpoint inhibitors, or even anti-androgens, all of wh

173 t to yield the full function of novel immune checkpoint inhibitors.

174 ome and may inform clinical trials of immune checkpoint inhibitors.

175 er immunotherapy, with an emphasis on immune checkpoint inhibitors.

176 e treatment of melanoma patients with immune checkpoint inhibitors.

177 in claudin-low tumors, treatment with immune checkpoint inhibitory antibodies against cytotoxic T lym

178 The mitotic checkpoint is a cellular safeguard that prevents chromos

179 The checkpoint is activated by unattached kinetochores, and

180 This innate immune checkpoint is composed of what has become known as the '

181 This checkpoint is located after the Gln checkpoint and befor

182 he key signal amplification reaction for the checkpoint is the conformational conversion of "open" mi

183 diated by the ATM and Rad3-related (ATR) and checkpoint kinase 1 (CHK1) kinases to transiently suppre

184 rogates for the LRRK2 kinase domain based on checkpoint kinase 1 (CHK1) mutants were designed, expres

185 ociated with elevated levels of IL-1beta and checkpoint kinase 1 phosphorylation.

186 checkpoint arrest due to phosphorylation of checkpoint kinase 1.

187 phohistone H2A (gammaH2A) formed by Rad3/ATR checkpoint kinase at DNA lesions; however, the putative

188 depends on FANCI and on the activity of the checkpoint kinase ATR.

189 serine 345 phosphorylation of the DNA damage checkpoint kinase Chk1 by Rad3 (ATR) at broken replicati

190 arly CHEK1, which encodes for the cell cycle checkpoint kinase CHK1, is significantly overexpressed i

191 Furthermore, Ape1, coordinated with checkpoint kinase Chk2, regulates drug response of gliob

192 Checkpoint kinase inhibitors (CHKi) exhibit striking sin

193 The spindle assembly checkpoint kinase Mps1 not only inhibits anaphase but al

194 The master spindle checkpoint kinase Mps1 senses kinetochore-microtubule at

195 han even AlaRS, the only ubiquitous cellular checkpoint known for clearing the error.

196 G1-S checkpoint loss contributes to carcinogenesis and increa

197 Immune checkpoint markers and molecular signatures of macrophag

198 Therefore, the G1-S checkpoint may be affected by knockdown of both proteins

199 CD39 and CD73 is a newly recognized "immune checkpoint mediator" that interferes with anti-tumor imm

200 who have been treated with different immune checkpoint modulators, form the rationale for the design

201 noma cells express high levels of the immune checkpoint molecule CTLA4, with important possible impli

202 l Activation (VISTA) is an inhibitory immune-checkpoint molecule that suppresses CD4(+) and CD8(+) T

203 eptor on T cells that functions as an immune checkpoint molecule to enforce tolerance to cognate anti

204 New mAbs targeting different immune checkpoint molecules, such as TIM3, CD27, and OX40, are

205 ptosis and upregulation of inhibitory immune checkpoint molecules.

206 The DNA replication or S-phase checkpoint monitors the integrity of DNA synthesis.

207 on of both inhibitory and stimulatory immune checkpoints on individual cells within the tumor microen

208 Blocking these checkpoints on T cells has provided dramatic clinical be

209 ety of approaches-including targeting immune checkpoints other than PD-1; modulating tumor-associated

210 On Western blot analysis of pathway checkpoints, p-mTOR (p=0.03) and PI3K-alpha (P = 0.04) w

211 d regulation of Igo/ENSA in the context of a checkpoint pathway that links mitotic entry to membrane

212 Blockade of the PD-1/PD-L1 immune checkpoint pathway with monoclonal antibodies has provid

213 a decreased sensitivity to immunosuppressive checkpoint pathways to provide greater proliferative cap

214 inhibition, along with inhibition of immune checkpoints PD-1 and CTLA-4, induced complete and durabl

215 d to immunohistochemical analysis for immune checkpoints (PD-L1, PD-1, LAG-3) and immune cell (IC) su

216 neity may reflect a relaxation of cell cycle checkpoints, possibly increasing the ability of slow-gro

217 Mps-1 resulted in abrogation of the mitotic checkpoint, premature progression through mitosis, marke

218 plays a key role in advancing the DNA damage checkpoint process.

219 tion in response to irradiation, impaired G2 checkpoint proficiency and radiosensitization.

220 on and Xi heterochromatin maintenance in p21 checkpoint-proficient human cells.

221 TGFbeta1-induced DNA replication and mitotic checkpoint progression.

222 rexpression overrides the replication stress checkpoint, promoting continued origin firing.

223 -containing partner to be the DNA damage and checkpoint protein TOPBP1.

224 ed hTERT-RPE1 cells by codepletion of the Rb checkpoint protein, but more thorough suppression of the

225 e, we find that within minutes of DNA damage checkpoint proteins are assembled at the kinetochore, no

226 ratumoral HPV oncoproteins upregulate immune checkpoint proteins such as PD-1 to evade immune-mediate

227 4 and Apc15) regulate association of spindle checkpoint proteins, in the form of the mitotic checkpoi

228 rolling the levels of various DNA repair and checkpoint proteins; however, how the DDR communicates w

229 ncoding the immunotherapy target PD-1 immune checkpoint receptor and its ligands.

230 vivo PET imaging to dynamically track T-cell checkpoint receptor expression and localization in a hum

231 Antibody targeting of the immune checkpoint receptor PD1 produces therapeutic activity in

232 h profile of these mAbs block the inhibitory checkpoint receptors PD-1 and CTLA-4 and have improved l

233 observe alterations in cell-cycle and immune checkpoint regulation genes in post-treatment tumors.

234 This study showed that IFN-gamma is a master checkpoint regulator for many cytokines.

235 nd bone marrow cells and was implicated as a checkpoint regulator of inflammatory cytokines, as well

236 hese data indicate that KHSRP functions as a checkpoint regulator of the innate immune response to pa

237 Utilization of negative checkpoint regulators (NCRs) for cancer immunotherapy ha

238 mutp53 directly perturbs the DNA replication checkpoint remains unclear.

239 uce TopBP1 oligomerization and attenuate ATR checkpoint response during replication stress.

240 Paradoxically, ATR inhibits CDKs during checkpoint responses, but CDK activity is required for e

241 ng Thr-716, compromised MAD2 binding and the checkpoint responses.

242 hat T cell-derived CD70 plays a novel immune checkpoint role in inhibiting inflammatory T cell respon

243 mor models to identify the tumor-suppressive checkpoint role of TEC-expressed insulin growth factor (

244 The spindle assembly checkpoint (SAC) delays mitotic progression until all si

245 chromosome segregation, the spindle assembly checkpoint (SAC) prevents anaphase until all kinetochore

246 c exit is due to defects in spindle assembly checkpoint (SAC) signaling, such that cells are unable t

247 le; this is achieved by the Spindle Assembly Checkpoint (SAC) that inhibits the Anaphase Promoting Co

248 naling cascade known as the spindle assembly checkpoint (SAC) to detect and signal the lack of attach

249 bstantial impairment of the spindle assembly checkpoint (SAC), leading to a high rate of chromosome m

250 enesis, UVB-irradiated cells also activate a checkpoint signaling cascade mediated by the ATM and Rad

251 ing, phosphorylates multiple proteins in the checkpoint signaling cascade.

252 ess or DNA damage triggers fork stalling and checkpoint signaling to activate repair pathways.

253 etochore-microtubule attachment and promotes checkpoint signaling to ensure accurate chromosome segre

254 and correlates of bacterial killing, reduced checkpoint signaling, and the relocation of effector T c

255 assembly, basal replication stress, impaired checkpoint signaling, defective cell cycle control, and

256 Mps1, long known to be the 'boss' in mitotic checkpoint signaling, phosphorylates multiple proteins i

257 ogy, chromosome alignment, and stringency of checkpoint signaling, resulting in error-prone chromosom

258 and CTD) of MAD1 also contribute to mitotic checkpoint signaling.

259 se, providing critical insights into mitotic checkpoint signaling.

260 Mad1-Bub1 complex is formed during synthetic checkpoint signaling.

261 tion of PP2A(Cdc55) plays a critical role in checkpoint signaling.

262 cytokines that increase expression of T-cell checkpoint signals such as PD-L1, which may inhibit thei

263 mechanistic dissection of MCC generation and checkpoint silencing.

264 he ATPase TRIP13 promote MCC disassembly and checkpoint silencing.

265 activating negative regulatory pathways and checkpoints such as PD-1/PD-L1 and CTLA-4.

266 Treatments that target immune checkpoints, such as the one mediated by programmed cell

267 to complete genome replication and defective checkpoint surveillance enables BRCA2-deficient cells to

268 The mitotic checkpoint system prevents premature separation of siste

269 death ligand 1 (PD-L1) is part of an immune checkpoint system that is essential for preventing autoi

270 Here we establish PPM1A as a checkpoint target used by Mtb to suppress macrophage apo

271 a viable therapeutic approach for enhancing checkpoint-targeting immunotherapy protocols.

272 (Mps-1) is a kinase of the spindle assembly checkpoint that controls cell division and cell fate.

273 The recognition of CD16 as a major checkpoint that controls immune surveillance may promote

274 hlights the oxidative pathway as a metabolic checkpoint that controls Treg cell behavior and affects

275 d be a key modulator of a novel Golgi export checkpoint that coordinates GPCR delivery to the surface

276 pha (SIRPalpha) is a myeloid-specific immune checkpoint that engages the "don't eat me" signal CD47 e

277 t of A2A adenosine receptor (A2AR) acts as a checkpoint that limits the maturation of natural killer

278 These findings define a myeloid-based immune checkpoint that restricts T-cell trafficking into tumors

279 sphatase and tensin homolog (PTEN)-regulated checkpoint that retains deltaR in the Golgi and decrease

280 imulation and triggering of immunoregulatory checkpoints that attenuate T-cell responses.

281 gs identify context-specific miRNA-regulated checkpoints that control myelinogenesis and a therapeuti

282 Here, we review the use of checkpoints that govern the entry into sporulation in B.

283 dent and -independent mechanisms to abrogate checkpoints that prevent conversion of differentiated ac

284 esponse triggered by a "chromatid separation checkpoint" that delays nuclear envelope reassembly and,

285 cacy of adoptive T-cell therapies and immune checkpoint therapies in myelogenous leukemia are desired

286 Immune checkpoint therapies target tumor antigen-specific T cel

287 cancer does not appear to respond to immune checkpoint therapies where T-cell infiltration may be a

288 gnostic tool to predict patient responses to checkpoint therapies.

289 linical trial, testing enhancement of immune checkpoint therapy for NSCLC.

290 All immune checkpoint therapy is recommended alone plus in the abse

291 The impact of PD-1 immune checkpoint therapy prompts exploration of other strategi

292 irst-line chemotherapy, without prior immune checkpoint therapy, if NSCLC tumor is positive for PD-L1

293 potential mediators of resistance to immune checkpoint therapy.

294 IFN signaling and improve response to immune checkpoint therapy.

295 ports engagement of the AMPK-TORC1 metabolic checkpoint, thereby protecting tumour cells from MYC-dri

296 polarization, with ILC2s mediating an innate checkpoint to control adaptive T helper responses, which

297 short-lived activated form may function as a checkpoint to ensure proper splicing of certain pre-mRNA

298 stimulatory molecule CD80 and functions as a checkpoint to regulate immune responses.

299 on involves a novel, DDR-independent S-phase checkpoint, triggered by appressorium turgor generation

300 wed here that E7 abrogated the G1 cell cycle checkpoint under hypoxia and analyzed key cell cycle rel